人民财讯1月23日电，2026年1月23日中国人民银行以固定利率、数量招标方式开展了1250亿元7天期逆 回购操作，操作利率1.40%。 ...

通报还提到，近期关注到有人通过媒体发布《*ST立方回应风险提示：多措并举应对挑战股票20日复 牌》等信息，涉嫌存在不真实、不准确、不完整情形和误导性陈述，公司已通过法定渠道予以公告澄 清，安徽证监局将依法开展监管处置，并郑重提醒，*ST立方存在重大违法强制退市风险，请广大投资 者以公司正式公告内容为准，理性投资，避免被不实信息误导，造成损失。 人民财讯1月23日电，1月23日，安徽证监局发布关于*ST立方（300344）相关情况的通报。通报指出， *ST立方因2021年、2022年、2023年连续三年年度报告财务数据涉嫌虚假记载，触及《创业板股票上市 规则》关于重大违法强制退市情形的规定，公司股票可能被强制退市，安徽证监局已于2025年11月28日 下发《行政处罚及市场禁入事先告知书》。通报指出，拟处罚对象提出延期申辩和听证的申请，安徽证 监局已依法准予延期，目前正抓紧开展相关工作，后续将依法做出行政处罚决定。 ...

人民财讯1月23日电，商务部消息，1月15日，商务部副部长兼国际贸易谈判副代表凌激会见英国驻华大 使魏磊。 ...

人民财讯1月23日电，国内期市早盘开盘多数上涨。涨幅方面，合成橡胶涨停，铂涨超10%，沪银涨超 6%，钯涨超5%，苯乙烯、碳酸锂、PTA、橡胶、20号胶、沪金涨超2%。 ...

Group 1 - A-shares experienced a volatile upward trend on Thursday, with major indices closing higher, indicating a potential short-term consolidation phase after recent gains [1][2] - Positive factors such as the "14th Five-Year" industrial guidance, overseas liquidity easing, and domestic policy support are expected to provide ongoing support for the A-share market [1] - Market sentiment is gradually improving, with structural opportunities remaining as daily trading volume stays above 2.5 trillion yuan [1] Group 2 - The market showed a mixed performance with most sectors rising, and recent hot themes experiencing orderly rotation, maintaining high investor sentiment and profitability [2] - Oil and gas extraction and military industries attracted continuous capital attention, while previously strong precious metals sectors began to show significant differentiation [2] - The semiconductor sector, which had previously shown strong performance, experienced a pullback, indicating internal differentiation within the sector [2]

马斯克补充道："我认为到明年年底，我们就能向公众出售人形机器人了。届时，你基本上可以让它做 任何你想让它做的事情。" 当地时间1月22日，马斯克表示，特斯拉计划在2027年底前向公众出售Optimus机器人。马斯克在瑞士达 沃斯世界经济论坛上发表讲话称："人形机器人技术将发展得非常迅速。我们已经有一些特斯拉Optimus 机器人在工厂里执行一些简单的任务，可能在今年晚些时候，我认为它们将能够执行更复杂的任务，并 且会在工业环境中部署。" ...

微软在社交媒体上发文称，其支持团队正在调查此次服务中断事件。调查人员将问题归咎于服务基础设 施。微软在美东时间下午6点21分的社交媒体帖子中表示："我们正在重新平衡所有受影响基础设施上的 流量，以确保环境恢复到平衡状态。" 美国东部时间1月22日下午2点40分左右，微软多项服务突然中断，导致用户无法使用Office、Outlook、 Teams等服务。据故障追踪网站DownDetector的数据显示，当天下午3点左右，超过15000名用户报告了 Microsoft365产品使用问题。另有12000名用户报告了Microsoft Outlook问题，500名用户报告了Microsoft Teams问题。 ...

公司预计今年第一季度营收在117亿至127亿美元之间，低于分析师预期的中值；预计调整后EPS为零， 远低于分析师预期的0.08美元；预计调整后毛利率为34.5%，低于分析师预期。 管理层将一季度指引疲软主要归因于制造良率问题导致的供应短缺。预计供应问题将在第一季度达到峰 值，并从第二季度开始逐步改善。 英特尔去年第四季度营收为136.7亿美元，同比下降4.1%，但高于分析师预期的134.3亿美元；调整后每 股收益(EPS)为0.15美元，同比增长15.4%，远超分析师预期的0.087美元。 数据中心和AI(DCAI)业务收入为47.4亿美元，同比增长8.9%，超出市场预期。 ...

Core Insights - Qwen3-TTS is an open-source voice generation model developed by Qwen, offering two model sizes: 1.7B for extreme performance and control, and 0.6B for a balance of performance and efficiency, supporting 10 major languages and various dialects [1] - The model features capabilities for voice cloning, voice creation, and high-quality human-like voice generation, driven by natural language instructions to flexibly control acoustic attributes such as tone, emotion, and rhythm [1] - It utilizes an innovative Dual-Track hybrid streaming generation architecture, allowing for both streaming and non-streaming generation, with an end-to-end synthesis delay as low as 97ms, catering to real-time interaction needs [1] Performance Metrics - Qwen3-TTS-VoiceDesign surpasses MiniMax-Voice-Design and other open-source models in instruction-following capability and expressiveness in the InstructTTS-Eval [2] - Qwen3-TTS-Instruct demonstrates single-speaker multilingual generalization with an average word error rate of 2.34%, maintaining style control at 75.4% in InstructTTS-Eval, and excels in long speech generation with word error rates of 2.36% for Chinese and 2.81% for English in 10-minute speech [2] - Qwen3-TTS-VoiceClone outperforms MiniMax and ElevenLabs in stability for Chinese and English cloning, average word error rates across multilingual test sets, and speaker similarity [2]

Core Viewpoint - Bangshun Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the exclusive sponsor. The company focuses on oncology and autoimmune diseases, with a pipeline that includes one NDA-stage product, one registration clinical-stage product, and five preclinical candidates [1]. Company Summary - The core product, Bezeqitinib, is a JAK inhibitor expected to be among the first domestically approved treatments for myelofibrosis (MF) in China, with an NDA submitted and approval anticipated in Q2 2026. It is also a leading JAK inhibitor for treating polycythemia vera (PV) in China and essential thrombocythemia (ET) globally [1]. - Another key product, CX1440, is a BTK inhibitor currently in Phase III clinical trials, ranking among the top three globally for treating immune thrombocytopenia (ITP) and among the top two for chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA) [1]. Industry Summary - The Chinese myeloproliferative neoplasm (MPN) market is projected to grow from $900 million in 2024 to $1.6 billion by 2030. The market for autoimmune disease drugs in China is expected to increase from $4.6 billion in 2024 to $18.4 billion by 2030 [1].